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isations due to adverse events, and other medical resources
(blood transfusions, onerous concomitant medications) for each
regimen to provide total cost per patient. RESULTS: In France,
the total treatment costs per patient by 21 months were 10,957€
for Gem/Cis, 12,512€ for Vin/Cis and 13,268€ for Pac/Car. The
average number of chemotherapy cycles in the clinical trial was
4.02, 4.23, and 3.25 for Gem/Cis, Pac/Carbo and Vin/Cis,
respectively, giving a lower total treatment cost per chemother-
apy cycle for Gem/Cis (2721€) than for Pac/Car (3136€) or
Vin/Cis (3850€). The total cost difference between Gem/Cis and
Pac/Car (2330€) was mainly due to the highest chemotherapy
acquisition costs for Pac/Car, which were not offset by lower
costs elsewhere. The difference in total costs between Gem/Cis
and Vin/Cis (1575€) were due primarily to the higher rate of hos-
pitalisation in the Vin/Cis group. CONCLUSIONS: Gem/Cis
administered as a 3-week cycle incurs lower costs per patient
than a 3-week cycle of Pac/Carbo and a 4-week cycle of Vin/Cis
when other direct costs are considered in addition to chemother-
apy acquisition costs. Notably, hospitalisation costs due to
adverse events are a major cost driver for some chemotherapy
regimens.
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OBJECTIVES: Novel chemotherapy regimens are cost-effective
relative to best supportive care in the treatment of patients 
with advanced non-small cell lung cancer (NSCLC). A recently
published randomised controlled clinical trial demonstrated 
that gemcitabine/cisplatin (Gem/Cis), paclitaxel/carboplatin
(Pac/Carbo) and vinorelbine/cisplatin (Vin/Cis) were equally
effective with regards to overall survival and time to disease pro-
gression in Italian patients with advanced NSCLC. We per-
formed a retrospective economic analysis to compare these three
combination regimens from the perspective of the German health
care system. METHODS: Cost-minimisation and cost-effective-
ness analyses were based on resource use and efﬁcacy data from
the clinical trial of Scagliotti et al. (2002). The following direct
treatment-related costs were identiﬁed for each chemotherapy
regimen: chemotherapy acquisition, drug administration, hospi-
talisations, and other medical resources. Unit costs of medical
resources in Germany were derived from ofﬁcial published
sources. Cost-effectiveness results were calculated by dividing the
mean total treatment cost per patient by the mean number of
extra life-months gained or by the mean number of months free
of disease progression per patient treated. RESULTS: The
average total treatment costs per patient were 15,211€ for
Pac/Carbo, 8738€ for Gem/Cis, and 9721€ for Vin/Cis. The
incremental cost-effectiveness ratio for Pac/Carbo vs Gem/Cis
was 65,000€ per additional life-month gained. Incremental
analysis showed Gem/Cis to dominate Vin/Cis with additional
survival achieved for less cost. CONCLUSIONS: Based on
resource use and efﬁcacy data from the same clinical trial,
Gem/Cis is a cost-effective combination chemotherapy regimen
for the treatment of advanced NSCLC in Germany.
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OBJECTIVES: Platinum-based combination chemotherapy regi-
mens with new agents such as gemcitabine, paclitaxel and
vinorelbine have been investigated for the treatment of non-
small-cell lung cancer (NSCLC), but no speciﬁc regimen has
proven superiority in terms of prolonged survival. Assessing the
costs of treatment and establishing which regimens provide value
for money are important issues for Health Care providers. This
study aimed to compare the mean total treatment costs of three
novel chemotherapy regimens from the perspective of the UK
National Health Service (NHS). METHODS: Resource utilisa-
tion and clinical outcome data were drawn from Scagliotti et al.
(2002), a prospective, randomised, controlled trial of gemc-
itabine/cisplatin (Gem/Cis), paclitaxel/carboplatin (Pac/Carbo)
and vinorelbine/cisplatin (Vin/Cis) in 612 chemotherapy-naïve
patients with locally advanced NSCLC. No statistically signiﬁ-
cant differences were found between the treatment options in
terms of progression-free and overall survival and, accordingly,
a cost-minimisation analysis was conducted. Only direct medical
resource costs were included in the analysis. Costs were com-
pared across four main resource categories: chemotherapy acqui-
sition, drug administration, hospitalisations associated with
adverse events and other medical resources. UK health care unit
costs were derived from published literature and public NHS
sources. RESULTS: Patients treated with Gem/Cis had lower
mean total treatment costs (£6688) than patients treated with
Pac/Carbo (£10,203) or Vin/Cis (£7102). Chemotherapy acqui-
sition was the major cost component for Gem/Cis and Pac/Carbo
patients (51% and 79% of total costs per patient, respectively),
whereas chemotherapy acquisition and hospitalisations
accounted for 31% and 32%, respectively, of the total per-
patient costs of the Vin/Cis regimen. CONCLUSIONS: For treat-
ment of advanced NSCLC in the UK, Gem/Cis is associated 
with lower direct treatment-related costs than Pac/Carbo or
Vin/Cis. This analysis presents evidence that the Gem/Cis regime
provides greater value for money to fund-holders with a limited
budget.
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OBJECTIVES: A prospective randomised controlled Phase III
clinical trial demonstrated that three platinum-based chemother-
apeutic regimens with novel agents—gemcitabine/cisplatin
(Gem/Cis), paclitaxel/carboplatin (Pac/Carbo) and vinorelbine/
cisplatin (Vin/Cis)—had comparable efﬁcacy in chemotherapy-
naive Italian patients with advanced non-small cell lung cancer
(NSCLC): median survival times ranged from 9.5 to 9.9 months
and median time to progression ranged from 4.6 to 5.5 months
(Scagliotti et al. 2002). As part of the Gemzar Retrospective Eco-
nomic Analysis of clinical Trials (GREAT2), we performed a ret-
rospective cost comparison of these three chemotherapeutic
regimens from the perspective of the Italian health care system.
METHODS: The analysis involved costing of chemotherapy and
medical resource utilisation collected prospectively during the
trial published by Scagliotti et al. (2002). Direct costs were com-
